ScreenerHero

OXB Oxford Biomedica PLC

LSE · GB · Healthcare · Biotechnology · oxb.com
544.00GBP+6.88%Mkt Cap: 844.57M $P/E: —

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system wh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap844.57M USD
Enterprise Value897.11M USD
Revenue (TTM)224.92M USD
Gross Profit84.63M USD
Net Income (TTM)-38.64M USD
Revenue/Share1.47 GBP
Last Price544.00 GBP
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.0K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BDFBVT43
Valuation
P/E (Trailing)—
P/E (Forward)-69.61
PEG—
EV/EBITDA-30.78
EV/Revenue3.99
P/S3.51
P/B10.60
EPS (TTM)-0.32
EPS (Forward)-0.07
52W Range
420.0023% of range962.00
52W High962.00 GBP
52W Low420.00 GBP
Profitability
Gross Margin39.10%
Oper. Margin-26.85%
EBITDA Margin-12.96%
Profit Margin-17.85%
ROE-32.98%
ROA-9.25%
Growth
Revenue Growth9.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF650.28K USD
CapEx (TTM)6.11M USD
FCF Margin-14.78%
FCF Yield-3.94%
Net Debt106.92M USD
Net Debt/EBITDA-3.67
Balance Sheet
Debt/Equity1.62
Current Ratio2.21
Quick Ratio1.76
Book Value/Sh0.48 GBP
Cash/Share0.62 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 30, 2018
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)703.50 GBP
Upside (mean)+29.3%
Target Range508.00 GBP – 900.00 GBP
508.00+29.3% to mean900.00
# Analysts8
Ownership
Shares Out.121.04M
Float60.76M
Insiders20.57%
Institutions65.29%
Technical
SMA 50501.09 (+8.6%)
SMA 200621.59 (-12.5%)
Beta1.09
S&P 52W Chg13.94%
Avg Vol (30d)798.50K
Avg Vol (10d)603.53K
Technical Indicators
RSI (14)62.4
MACD6.0562
MACD Signal-4.7177
MACD Hist.+10.7738
BB Upper540.00 GBP
BB Middle477.35 GBP
BB Lower414.70 GBP
BB Width26.25%
ATR (14)28.48 GBP
Vol Ratio (20d)0.97x